Zsolt Dubravcsik1, László Madácsy2, Tibor Gyökeres3, Áron Vincze4, Zoltán Szepes5, Péter Hegyi6, István Hritz7, Attila Szepes8. 1. Department of Gastroenterology and Endoscopy, Bács-Kiskun County Hospital, Nyíri út 38, 6000 Kecskemét, Hungary. Electronic address: dubravcsikzs@gmail.com. 2. 2nd Department of Internal Medicine, Semmelweis University, Szentkirályi u. 46, 1088 Budapest, Hungary. 3. Department of Gastroenterology, State Health Centre, Podmaniczky u. 111, 1062 Budapest, Hungary. 4. 1st Department of Internal Medicine, University of Pécs, Rákóczi út 2, 7622 Pécs, Hungary. 5. 1st Department of Internal Medicine, University of Szeged, Korányi fasor 8-10, 6720 Szeged, Hungary. 6. 1st Department of Internal Medicine, University of Szeged, Korányi fasor 8-10, 6720 Szeged, Hungary; MTA-SZTE Lendület Translational Gastroenterology Research Group, Korányi fasor 8-10, 6720 Szeged, Hungary. 7. Department of Gastroenterology and Endoscopy, Bács-Kiskun County Hospital, Nyíri út 38, 6000 Kecskemét, Hungary; 1st Department of Internal Medicine, University of Szeged, Korányi fasor 8-10, 6720 Szeged, Hungary. 8. Department of Gastroenterology and Endoscopy, Bács-Kiskun County Hospital, Nyíri út 38, 6000 Kecskemét, Hungary.
Abstract
BACKGROUND: The outcome of the most common biliary form of acute pancreatitis has not changed even with the better described indications for early endoscopic intervention. It may be due to the fact that this intrevention theoretically can cause further pancreatic injury or cannot always relieve the pancreatic duct obstruction. We hypothesize that maintaining the outflow of the pancreatic duct with preventive pancreatic stents at the early ERCP improves the outcome of acute biliary pancreatitis. METHODS/ DESIGN: PREPAST is a prospective, randomized, controlled, multicenter trial. Patients with acute biliary pancreatitis with coexisting cholangitis are randomized to undergo urgent endoscopic intervention with or without pancreatic stenting within 48 h from the onset of pain, and in addition patients without signs of cholangitis but cholestasis are randomly allocated to recieve conservative treatment or early endoscopic intervention with or without pancreatic stenting within 48 h from the onset of pain. Patients without acute cholangitis and signs of cholestasis recieve conservative treatment. 230 patients are planned to be enrolled during a 48 months period from different centers. The primary endpoint is the outcome of acute biliary pancreatitis as described by the latest guidelines. Secondary endpoints include mortality data, and other variables not analyzed as a primary endpoint but related to the pancreatitis or the pancreatic stenting. DISCUSSION: The PREPAST trial is designed to show whether early endoscopic intervention with the usage of preventive pancreatic stenting improves the outcome of acute biliary pancreatitis. The study has been registered at the International Standard Randomised Controlled Trial Number (ISRCTN) Register (trial ID: ISRCTN13517695).
RCT Entities:
BACKGROUND: The outcome of the most common biliary form of acute pancreatitis has not changed even with the better described indications for early endoscopic intervention. It may be due to the fact that this intrevention theoretically can cause further pancreatic injury or cannot always relieve the pancreatic duct obstruction. We hypothesize that maintaining the outflow of the pancreatic duct with preventive pancreatic stents at the early ERCP improves the outcome of acute biliary pancreatitis. METHODS/ DESIGN: PREPAST is a prospective, randomized, controlled, multicenter trial. Patients with acute biliary pancreatitis with coexisting cholangitis are randomized to undergo urgent endoscopic intervention with or without pancreatic stenting within 48 h from the onset of pain, and in addition patients without signs of cholangitis but cholestasis are randomly allocated to recieve conservative treatment or early endoscopic intervention with or without pancreatic stenting within 48 h from the onset of pain. Patients without acute cholangitis and signs of cholestasis recieve conservative treatment. 230 patients are planned to be enrolled during a 48 months period from different centers. The primary endpoint is the outcome of acute biliary pancreatitis as described by the latest guidelines. Secondary endpoints include mortality data, and other variables not analyzed as a primary endpoint but related to the pancreatitis or the pancreatic stenting. DISCUSSION: The PREPAST trial is designed to show whether early endoscopic intervention with the usage of preventive pancreatic stenting improves the outcome of acute biliary pancreatitis. The study has been registered at the International Standard Randomised Controlled Trial Number (ISRCTN) Register (trial ID: ISRCTN13517695).
Authors: Andrea Szentesi; Emese Tóth; Emese Bálint; Júlia Fanczal; Tamara Madácsy; Dorottya Laczkó; Imre Ignáth; Anita Balázs; Petra Pallagi; József Maléth; Zoltán Rakonczay; Balázs Kui; Dóra Illés; Katalin Márta; Ágnes Blaskó; Alexandra Demcsák; Andrea Párniczky; Gabriella Pár; Szilárd Gódi; Dóra Mosztbacher; Ákos Szücs; Adrienn Halász; Ferenc Izbéki; Nelli Farkas; Péter Hegyi Journal: PLoS One Date: 2016-10-24 Impact factor: 3.240
Authors: Dezső Kelemen; Péter Hegyi; Levente Pál Kucserik; Katalin Márta; Áron Vincze; György Lázár; László Czakó; Zsolt Szentkereszty; Mária Papp; Károly Palatka; Ferenc Izbéki; Áron Altorjay; Imola Török; Sorin Barbu; Marcel Tantau; András Vereczkei; Lajos Bogár; Márton Dénes; Imola Németh; Andrea Szentesi; Noémi Zádori; Judit Antal; Markus M Lerch; John Neoptolemos; Miklós Sahin-Tóth; Ole H Petersen Journal: BMJ Open Date: 2019-07-09 Impact factor: 2.692
Authors: Balázs Koncz; Erika Darvasi; Dalma Erdősi; Andrea Szentesi; Katalin Márta; Bálint Erőss; Dániel Pécsi; Zoltán Gyöngyi; János Girán; Nelli Farkas; Maria Papp; Eszter Fehér; Zsuzsanna Vitális; Tamás Janka; Áron Vincze; Ferenc Izbéki; Veronika Dunás-Varga; László Gajdán; Imola Török; Sándor Károly; Judit Antal; Noémi Zádori; Markus M Lerch; John Neoptolemos; Miklós Sahin-Tóth; Ole H Petersen; Péter Hegyi Journal: BMJ Open Date: 2020-01-06 Impact factor: 2.692
Authors: Katalin Márta; Anikó N Szabó; Dániel Pécsi; Péter Varjú; Judit Bajor; Szilárd Gódi; Patrícia Sarlós; Alexandra Mikó; Kata Szemes; Mária Papp; Tamás Tornai; Áron Vincze; Zsolt Márton; Patrícia A Vincze; Erzsébet Lankó; Andrea Szentesi; Tímea Molnár; Roland Hágendorn; Nándor Faluhelyi; István Battyáni; Dezső Kelemen; Róbert Papp; Attila Miseta; Zsófia Verzár; Markus M Lerch; John P Neoptolemos; Miklós Sahin-Tóth; Ole H Petersen; Péter Hegyi Journal: BMJ Open Date: 2017-09-14 Impact factor: 2.692
Authors: Andrea Szentesi; Andrea Párniczky; Áron Vincze; Judit Bajor; Szilárd Gódi; Patricia Sarlós; Noémi Gede; Ferenc Izbéki; Adrienn Halász; Katalin Márta; Dalma Dobszai; Imola Török; Hunor Farkas; Mária Papp; Márta Varga; József Hamvas; János Novák; Artautas Mickevicius; Elena Ramirez Maldonado; Ville Sallinen; Dóra Illés; Balázs Kui; Bálint Erőss; László Czakó; Tamás Takács; Péter Hegyi Journal: Front Physiol Date: 2019-09-20 Impact factor: 4.566